EURONEXT-PAR$GNFTY
Genfit · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
GENFIT Q1 2025: €2.8M Iqirvo royalties lift cash to €129.5M after HCRx financing
GENFIT reported first quarter 2025 financial information on May 22 with revenues of €2.8 million, up from €1.1 million in Q1 2024, entirely from royalties on Ipsen sales of Iqirvo (elafibranor). Cash and cash equivalents rose to €129.5 million at March 31, 2025 from €81.8 million at year-end 2024, reflecting a €130.0 million first installment from the HCRx royalty financing partly offset by a €61.7 million repurchase of 2025 OCEANEs. Management said the royalty financing extends cash runway beyond the end of 2027 while the company advances ACLF pipeline programs including UNVEIL-IT, GNS561, G1090N, SRT-015, and CLM-022. The release also noted an upcoming €26.5 million milestone from Italian pricing and reimbursement approval for Iqirvo and announced that Chief Medical Officer Carol Addy will retire effective June 30, 2025.
- Q1 2025 revenues were €2.8 million versus €1.1 million a year ago, driven by Iqirvo royalties from Ipsen.
- Cash and cash equivalents totaled €129.5 million at March 31, 2025, up from €81.8 million at December 31, 2024.
- The HCRx royalty financing provided a €130.0 million upfront installment, partly offset by €61.7 million of OCEANE repurchases.
- Management expects cash runway beyond end-2027 assuming future Ipsen milestones, royalty financing drawdowns, and OCEANE maturity reimbursement.
- Chief Medical Officer Carol Addy will retire effective June 30, 2025.
Headline financials
Revenue & EPS history
Genfit · Revenue · Quarterly
€3.11M
Revenue by segment
Genfit · €2.8M total across 1 segment · Q1 2025
- Iqirvo royalties from Ipsen€2.8M—100.0%
Forward guidance
GENFIT expects cash runway beyond the end of 2027 based on current programs, anticipated Ipsen milestone revenue, additional royalty financing installments, and OCEANE reimbursement at maturity.
Tailwinds
- Non-dilutive HCRx royalty financing strengthened the balance sheet with €130.0 million upfront.
- Company expects a €26.5 million milestone following Italian pricing and reimbursement approval for Iqirvo.
Headwinds
- Ongoing R&D spending across multiple ACLF and cholangiocarcinoma programs continues to consume cash.
- Revenue remains heavily dependent on Ipsen Iqirvo royalties and milestone payments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q1 2025
-0.4%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+11.5%
Q2 2024
Best reaction
-7.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q4 2025 | -2.1% | -9.9% | -10.5% | |
| Q1 2025 | -1.2% | -1.2% | +25.8% | |
| Q2 2024 | +11.5% | +21.7% | +36.9% | |
| Q4 2023 | +4.7% | +0.3% | +4.9% | |
| Q3 2023 | -4.6% | -5.2% | -4.3% | |
| Q2 2023 | -7.7% | -4.7% | -8.6% | |
| Q4 2022 | -3.2% | -4.5% | -0.7% | |
| Q3 2022 | -2.8% | -0.3% | +3.6% | |
| Q2 2022 | -3.0% | +0.0% | +28.0% | |
| Q4 2021 | +2.0% | -5.9% | -18.6% | |
| Q2 2021 | +0.5% | +2.6% | -1.6% | |
| Q4 2020 | -1.2% | +0.4% | +0.0% | |
| Q2 2020 | -0.4% | -1.8% | -13.5% | |
| Q4 2019 | +3.4% | +2.6% | -11.5% | |
| Q3 2019 | -4.6% | -9.6% | -9.3% | |
| Q2 2019 | +0.8% | -2.1% | -10.8% | |
| Q1 2019 | +0.5% | -0.2% | +4.5% | |
| Q4 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro